DendroPharm
DendroPharm GmbH is a Berlin-based company specializing in the development and manufacturing of nanocarriers, drug delivery systems, and pharmaceutical excipients. The company focuses on innovative therapies, custom synthesis, formulation development, and contract manufacturing, with a strong emphasis on nanotechnology and bio-compatible dendritic core-multishell nanocarriers. It aims to improve drug bioavailability, reduce side effects, and develop new drug delivery systems for human and veterinary medicine. DendroPharm collaborates with research institutions and industry partners, and is certified according to ISO 9001:2015 and GMP standards.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Amphiphilic skin-penetrating nanocarrier
Amphiphilic dendritic core–multishell nanocarrier designed to enhance transdermal penetration of both lipophilic and hydrophilic compounds and increase apparent solubility and bioavailability.
pH-cleavable tumor-accumulating nanocarrier
Core–multishell nanocarrier series engineered for selective accumulation in tumor tissue with pH-dependent drug release enabling controlled payload release in the tumor microenvironment.
Sulfated multivalent anti-inflammatory nanomaterial
Highly sulfated multivalent nanomaterial with strong binding to selectins and reported anti-inflammatory and antithrombotic activity functioning as a heparin-analogue scaffold.
GMP Auftragsfertigung halbfest und flüssig
Contract manufacturing services for non-sterile semi-solid and liquid pharmaceutical drugs, clinical trial samples, and cosmetics, including stability studies and QP release.
GMP Herstellung von Kleinchargen (Halbfeste & Flösige Arzneimittel)
Contract manufacturing services providing GMP-compliant production of small batches up to 50 liters for unsterile semi-solid and liquid pharmaceuticals and cosmetics.
GMP Kleinserien- und Testmusterproduktion
Contract manufacturing of test samples and small series up to 50 liters for unsterile semi-solid and liquid pharmaceuticals and cosmetics.
Amphiphilic skin-penetrating nanocarrier
Amphiphilic dendritic core–multishell nanocarrier designed to enhance transdermal penetration of both lipophilic and hydrophilic compounds and increase apparent solubility and bioavailability.
pH-cleavable tumor-accumulating nanocarrier
Core–multishell nanocarrier series engineered for selective accumulation in tumor tissue with pH-dependent drug release enabling controlled payload release in the tumor microenvironment.
Sulfated multivalent anti-inflammatory nanomaterial
Highly sulfated multivalent nanomaterial with strong binding to selectins and reported anti-inflammatory and antithrombotic activity functioning as a heparin-analogue scaffold.
GMP Auftragsfertigung halbfest und flüssig
Contract manufacturing services for non-sterile semi-solid and liquid pharmaceutical drugs, clinical trial samples, and cosmetics, including stability studies and QP release.
GMP Herstellung von Kleinchargen (Halbfeste & Flösige Arzneimittel)
Contract manufacturing services providing GMP-compliant production of small batches up to 50 liters for unsterile semi-solid and liquid pharmaceuticals and cosmetics.
GMP Kleinserien- und Testmusterproduktion
Contract manufacturing of test samples and small series up to 50 liters for unsterile semi-solid and liquid pharmaceuticals and cosmetics.
Services
GMP-compliant production of clinical test samples and small-scale batches (semi-solid and non-sterile liquid formulations) including stability studies with GMP analytics.
Custom synthesis of functionalized polymers and building-block based core–multishell nanocarriers tailored to customer application requirements.
Analytical services including chromatographic analysis, light-scattering, spectroscopy, HPLC method development and validation for nanocarriers and formulations.
Development of transdermal and topical formulations and in vitro penetration/release testing using Franz diffusion cells and multiple skin and mucosal models.
Purification services (e.g., ultrafiltration) and downstream processing tailored to nanomaterial production.
Conduct of stability studies under controlled conditions and accelerated/stress testing following ICH principles.
GMP-compliant production of clinical test samples and small-scale batches (semi-solid and non-sterile liquid formulations) including stability studies with GMP analytics.
Custom synthesis of functionalized polymers and building-block based core–multishell nanocarriers tailored to customer application requirements.
Analytical services including chromatographic analysis, light-scattering, spectroscopy, HPLC method development and validation for nanocarriers and formulations.
Development of transdermal and topical formulations and in vitro penetration/release testing using Franz diffusion cells and multiple skin and mucosal models.
Purification services (e.g., ultrafiltration) and downstream processing tailored to nanomaterial production.
Conduct of stability studies under controlled conditions and accelerated/stress testing following ICH principles.
Expertise Areas
- Nanocarrier design and synthesis
- Transdermal and mucosal drug delivery
- Formulation development for semi-solid and topical products
- Analytical method development and characterization of nanomaterials
Key Technologies
- Core–multishell dendritic nanocarriers
- Building-block synthetic design
- Amphiphilic nanocarriers for skin penetration
- pH-cleavable nanocarriers for tumor targeting
News & Updates
In January 2023, DendroPharm received the manufacturing license for analytics and release of veterinary medical products.
In January 2022, DendroPharm was certified according to GMP standards.
In January 2019, DendroPharm relocated to a new facility with 800 m2 of cleanroom, laboratory, storage, and production space.
In October 2017, DendroPharm became a member of the research and development network for pharmaceutical solutions.
In December 2016, DendroPharm received the award for its nanocarrier technology enabling transdermal drug transfer.
DendroPharm develops nanocarriers for veterinary applications, enhancing drug delivery and reducing side effects.
In January 2023, DendroPharm received the manufacturing license for analytics and release of veterinary medical products.
In January 2022, DendroPharm was certified according to GMP standards.
In January 2019, DendroPharm relocated to a new facility with 800 m2 of cleanroom, laboratory, storage, and production space.
In October 2017, DendroPharm became a member of the research and development network for pharmaceutical solutions.
In December 2016, DendroPharm received the award for its nanocarrier technology enabling transdermal drug transfer.
DendroPharm develops nanocarriers for veterinary applications, enhancing drug delivery and reducing side effects.